Article Figures & Data
Figures
- Figure 1 Patient disposition in Teriflunomide Multiple Sclerosis Oral (TEMSO) and the TEMSO extension study
a The major reason for screening failure was failure to meet inclusion criteria (n = 155 [62.0%]); b 2 patients (1 each in the 14-mg and 7-mg teriflunomide groups) were not exposed to study medication because of protocol violation; c did not give consent to continue in extension study; d 2 patients in the 14-mg/14-mg group were randomized but not treated: 1 did not wish to continue and the other 1 prematurely discontinued study treatment and did not take any double-blind medication in the extension.
- Figure 2 Efficacy outcomes in the core Teriflunomide Multiple Sclerosis Oral (TEMSO) and extension studies (modified intent-to-treat population)
(A) Annualized relapse rate. (B) Mean EDSS score. (C) Number of Gd-enhancing T1 lesions. a Patients receiving placebo in the core study are shown as one group for this analysis. Week refers to time since start of core study. Week 108 is end of core study/start of extension study. Total number of Gd-enhancing T1 lesions defined as all lesions enhanced on T1 scan. *p < 0.005 compared with pooled placebo group; **p < 0.05 compared with placebo/7-mg group. CI = confidence interval; EDSS = Expanded Disability Status Scale; Gd = gadolinium.
Tables
Data Supplement
One appendix, three tables, and two figures; three PDF files.
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2016 American Academy of Neurology.
Files in this Data Supplement:- Appendix e-1 - PDF file
- Tables e-1 to e-3 - PDF file
- Figures e-1 to e-2 - PDF file
Coinvestigators
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2016 American Academy of Neurology.
Files in this Data Supplement:- Coinvestigators - Microsoft Word file
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.